USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy

Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers

Healthcare Triangle partners with Cynomi to enhance cybersecurity in healthcare

Aster DM Healthcare concludes separation of India and GCC businesses

The company plans to add 1700 beds by FY27 through the organic route

UroGen Pharma files patent infringement action against Teva Pharmaceuticals

Evonik unveils latest global trial results MetAMINO

Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024

Colgate Active Salt redefines oral hygiene with a new and improved formula

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus